Obstetrics/Gynecology General
RSSArticles
-
Research Examines Effect of Pregnancy Preferences on Contraceptive Use
Researchers found that women with a strong preference to avoid pregnancy were far more likely to use any contraceptive method. However, more than 50% of women who reported a low preference to avoid pregnancy used some form of birth control.
-
Postpartum LARC: Highly Effective, but Restricted by Some Hospitals
Women who receive care in Catholic facilities may be denied postpartum LARC due to religious directives that ban such care. In 10 states, more than 30% of all hospital beds are in Catholic facilities. In about 50% of states, more than one in five hospital beds is in a Catholic facility.
-
Progesterone After Mifepristone to Halt Medication Abortion: Is It Safe?
Results of a new study indicated that women who initiate medication abortion but opt to stop in the middle of treatment may be at risk for serious blood loss.
-
Researchers Examine Use of Dichloroacetate in Endometriosis Treatment
The authors of a new scientific paper indicate that dichloroacetate, investigated as a potential cancer treatment, may be effective against endometriosis. Finding a new treatment option would augment current treatment strategies of hormone therapy and surgery, which involve significant side effects and recurrence after treatment.
-
Research Focuses on Medroxyprogesterone Acetate in Cervical Cancer Prevention
Preliminary research suggests that medroxyprogesterone acetate, the active ingredient in the contraceptive injection DMPA, may be effective in preventing cervical cancer.
-
Policy Update Advocates Teen Access to Emergency Contraception
To help prevent unplanned pregnancy among adolescents, the American Academy of Pediatrics has issued an updated policy statement on emergency contraception (EC) to educate providers on use of EC in adolescents, and advocate for expanded access for teens.
-
Investigational Contraceptive Patch Clears FDA Panel Vote
Twirla, an investigational combined hormonal contraceptive patch, is under review by the FDA. In an October 2019 meeting, the patch received a 14 to 1 vote from the FDA’s Bone, Reproductive, and Urologic Drugs Advisory Committee.
-
FDA Approves Liletta IUD for Six Years of Effective Use
The FDA has approved the Liletta levonorgestrel intrauterine device (IUD) for six years of effective use. The 52 mg device, similar in size to the Mirena IUD, was approved for the U.S. in February 2015.
-
The Time for Contraceptive Revolution Is Now
While the 20th century yielded new contraceptives in the form of pills, rings, patches, intrauterine devices, and implants, it is time for new exploration into further birth control options.
-
The Affordable Care Act: Progress in Reducing the Rate of Unintended Pregnancy
Data from the latest release of the National Survey of Family Growth supports that the contraception coverage mandate of the Affordable Care Act has resulted in a decrease in the incidence of unintended pregnancy, particularly among women with government coverage.